Ian J. Dixon

FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease

F. Martinez, P. Calverley, R. Brook, 2020, International journal of chronic obstructive pulmonary disease.

A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [ 18 F ] FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer ’ s Disease

Thomas E. Nichols, P. Matthews, Brandon Whitcher, 2010 .

A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease.

Thomas E. Nichols, P. Matthews, Brandon Whitcher, 2011, Journal of Alzheimer's disease : JAD.

A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying

Thomas E. Nichols, P. Matthews, Brandon Whitcher, 2010 .

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease

F. Martinez, P. Calverley, R. Brook, 2018, Journal of the American College of Cardiology.

Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial

V. Kim, F. Martinez, P. Calverley, 2019, BMJ Open Respiratory Research.